Tetanus Toxoid Vaccine Market Report 2024

The tetanus toxoid vaccine market size has grown strongly in recent years. It will grow from $4.74 billion in 2023 to $5.08 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historic period can be attributed to several factors, including heightened awareness, a rise in tetanus cases, and government initiatives aimed at immunization programs.

The tetanus toxoid vaccine market size is expected to see strong growth in the next few years. It will grow to $6.74 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be attributed to heightened investments in research and development, along with the expansion of distribution networks. Key trends expected during this period include advancements in vaccine technology, the emergence of new markets, the introduction of innovative products and services, and a rising demand for vaccines.

The tetanus toxoid vaccine market is expected to grow due to increasing rates of preterm births. Preterm birth, occurring before 37 weeks of gestation, presents health challenges due to incomplete development. Factors contributing to this issue include advanced maternal age, lifestyle choices, medical interventions such as assisted reproductive technologies, maternal health conditions, and environmental factors. The rise in preterm birth rates drives demand for tetanus toxoid vaccines as more newborns and infants require immunization against tetanus and other preventable diseases. For example, the Office for National Statistics reported a slight increase in the percentage of preterm live births from 7.4% in 2020 to 7.5% in 2021 in the UK, highlighting the trend driving the tetanus toxoid vaccine market growth.

Leading companies in the tetanus toxoid vaccine market are focusing on developing advanced vaccines, such as the wP-IPV-based pentavalent vaccine, to meet increasing demand for comprehensive immunization solutions. The wP-IPV-based pentavalent vaccine combines multiple disease protections into a single injection, using inactivated bacteria and viruses to stimulate immunity without causing illness. For instance, Panacea Biotec Limited launched EasyFourPol in December 2023, a fully-liquid pentavalent vaccine that protects against Diphtheria, Tetanus, Pertussis, Polio, and Haemophilus Influenza Type B infections. This vaccine simplifies administration by eliminating the need for on-site preparation, ensuring efficient and effective immunization.

In March 2021, Stablepharma Ltd. partnered with BB-NCIPD Ltd. to develop a thermally stable, fridge-free version of the tetanus-diphtheria (Td) vaccine using Stablepharma's patented StablevaX formulation and device technology. This collaboration aims to enhance vaccine accessibility and stability, particularly in regions with limited refrigeration infrastructure. BB-NCIPD Ltd., based in Bulgaria, specializes in vaccine production, including the Tetanus Toxoid vaccine.

Major companies operating in the tetanus toxoid vaccine market are Sanofi S.A., Novartis AG, LG Chem Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Astellas Pharma Inc., CSL Limited, Zoetis Inc., Meiji Holdings Company Ltd., Walvax Biotechnology, Shenzhen Kangtai Biological Products Co. Ltd., AJ Vaccines AS, PT Bio Farma, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Amson Vaccines and Pharma Pvt Ltd., Incepta Vaccine Ltd., Mitsubishi Tanabe Pharma Corporation, BioNet-Asia Co. Ltd., Avalon Pharma Pvt. Ltd., Actiza Pharmaceutical Pvt. Ltd.

North America was the largest region in the tetanus toxoid vaccine market in 2023. The regions covered in the tetanus toxoid vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tetanus toxoid vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tetanus toxoid vaccine is designed to prevent tetanus, a severe bacterial infection caused by Clostridium tetani. It contains a form of the tetanus toxin, known as toxoid, which is harmless but prompts the immune system to generate antibodies against the toxin. These antibodies work by neutralizing the toxin produced by the bacteria, thereby providing protection against future infections.

The various types of tetanus toxoid vaccines are available. These include tetanus toxoid (Tt), diphtheria and tetanus (Dt), tetanus and diphtheria (Td), diphtheria, tetanus, and pertussis (Dtap), tetanus, diphtheria, and pertussis (Tdap), pentavalent, hexavalent, and others. Tetanus toxoid (Tt) vaccines consist of purified tetanus toxoid that stimulates the immune system to defend against tetanus-causing bacteria. These vaccines are used across different age groups, from pediatric to adult, in hospitals, clinics, government organizations, and other healthcare settings.

The tetanus toxoid vaccine market research report is one of a series of new reports that provides tetanus toxoid vaccine market statistics, including the tetanus toxoid vaccine industry global market size, regional shares, competitors with tetanus toxoid vaccine market share, detailed tetanus toxoid vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the tetanus toxoid vaccine industry. These tetanus toxoid vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tetanus toxoid vaccine market consists of sales of live, attenuated, inactivated, subunit, conjugate, and toxoid vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.